Lv11
60 积分 2025-01-23 加入
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
3小时前
待确认
The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact
4小时前
已完结
Risk stratification of metabolic disorder associated kidney disease
5天前
已完结
Recent advances in pathogenetic concepts and disease modeling of IgA nephropathy
10天前
已关闭
IgA Nephropathy and the Risk of Primary Infections: A Swedish population-based cohort study
1个月前
已关闭
Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users
1个月前
已关闭
Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop
1个月前
已完结
Obesity and Metabolic Health in CKD
1个月前
已关闭
Inflammatory Mechanisms in Obesity
1个月前
已完结
The Kinetics of Cystatin C and Serum Creatinine in Acute Kidney Injury
1个月前
已完结
皖公网安备34019202002308
